Retatrutide 10mg
Retatrutide injectable
RETA is a retatrutide injectable offered in 10mg and 30mg vial sizes for provider-directed metabolic care.
Important Research Notice
Research use only. Not for human consumption. This product is intended solely for laboratory research and educational applications. It is not designed for use in the diagnosis, treatment, cure, or prevention of any disease or medical condition. By purchasing this product, you acknowledge that this product is intended for research use only and agree to use it in accordance with all applicable laws and regulations.
People also buy
5-Amino-1MQ
Metabolic support compound
Tesamorelin
Growth hormone releasing factor analog
Tirzepatide
Dual GLP-1 / GIP receptor agonist
BPC-157
Recovery peptide
CJC-1295 (without DAC)
Growth hormone secretagogue peptide
CJC-1295 + Ipamorelin
Peptide blend
DSIP
Sleep support peptide
Epithalon
Longevity peptide
References
- Retatrutide 10mg - Peptide Center guide
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 TrialThe New England journal of medicine, 2023
- Retatrutide-A Game Changer in Obesity PharmacotherapyBiomolecules, 2025
- Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trialsDiabetes, obesity & metabolism, 2026
- Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USALancet (London, England), 2023
- Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trialNature medicine, 2024
- The power of three: Retatrutide's role in modern obesity and diabetes therapyEuropean journal of pharmacology, 2024